Video

Ilana Cass on Potential Consequences of Preventive Surgery

Author(s):

Ilana Cass, M.D.
Conference|FORCE Conference

Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.

Ilana Cass, M.D. of Cedars-Sinai Medical Center, discusses the potential side effects that may occur after a preventive surgery for ovarian cancer. Some of the effects are yet unknown and standards for screening need to be developed.

Related Videos
Image of woman with blonde hair.
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Image of bald man.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Related Content
Illustration of bladder.
February 21st 2025

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

Roman Fabbricatore
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of bladder cancer.
February 20th 2025

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Jax DiEugenio
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
In patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses. © stock.adobe.com.
February 18th 2025

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

Ashling Wahner
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.
Illustration of bladder.
February 18th 2025

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

Kristi Rosa
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.